Supporting patients' organizations

Pursuant to the Pharmaceutical Industry Code of Good Practices, each of its signatories is required to make publicly available lists of patients' organizations which they support financially or which receive vital tangible or intangible assistance (Art. 47 of the Code).

This list should include a brief description of the aid along with its value. In the case of substantial material assistance whose value is difficult to estimate, its description should include the characteristic of the benefits received by the patients’ organization.

This information is published on the website of the local pharmaceutical company, and in the absence thereof, on its global website or on the INFARMA website. According to the Code, this information should be updated at least once a year.

Support granted to patients' organizations by INFARMA member companies
AbbVie Polska Sp. z o.o.
Actelion Pharma Polska Sp. z o.o.
Allergan Sp. z o.o.
Amgen Biotechnologia Sp. z o.o.
Astellas Pharma Sp. z o.o.
AstraZeneca Pharma Poland Sp. z o.o.
Bayer Sp. z o.o.
Biogen Idec Poland Sp. z o.o.
Boehringer Ingelheim Sp. z o.o.
Bristol-Myers Squibb Polska Sp. z o.o.
Celgene Sp. z o.o.
Chiesi Poland Sp. z o.o.
Eli Lilly Polska Sp. z o.o.
GSK Commercial Sp. z o.o.
Ipsen Poland Sp. z o.o.
Janssen-Cilag Polska Sp. z o.o.
Lundbeck Poland Sp. z o.o.
Merck Sp. z o.o.
MSD Polska Sp. z o.o.
Novartis Poland Sp. z o.o.
Novo Nordisk Pharma Sp. z o.o.
Pfizer Polska Sp. z o.o.
Pierre Fabre Medicament Polska
Roche Polska Sp. z o.o.
Sanofi-Aventis Sp. z o.o.
Sanofi Pasteur Sp. z o.o.
Takeda Polska Sp. z o.o.
UCB Pharma Sp. z.o.o.
Support granted to patients' organizations by INFARMA 
Infarma 2014
© 2017 Infarma
page: 0,1082 s, time: 0,1097 s cache, query: 19, querytime: 0,0016 s